CYTK has been in the news 333% more than usual
Nov 05, 2025, 3:32 AM
8.68%
What does CYTK do
Cytokinetics, a South San Francisco-based biopharmaceutical company, develops muscle activators and inhibitors for diseases affecting muscle performance, with key drug candidates including aficamten and omecamtiv mecarbil. Founded in 2004, it employs 423 people and specializes in cardiac muscle function.
CYTK has been in the news recently: Cytokinetics is facing multiple class action lawsuits from investors alleging misleading statements regarding the FDA approval of aficamten between December 27, 2023, and May 6, 2025. Several law firms are encouraging affected shareholders to participate in these legal actions before the upcoming deadlines.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.